Renub Research

Prostate Drugs Market Share

Press Release   •   Jan 11, 2017 06:06 EST

Zytiga has highest market share in Prostate Cancer Market share globally. Zytiga is facing hard fight from Xtandi drugs which is anticipated to substitute Zytiga as the primary prostate cancer drugs in 2015. Zytiga was one of a small number of treatment choices for patients suffering from prostate cancer. This shows that most doctors prefer to treat patients with Zytiga drug despite its side effects. Before September 10, 2014 Xtandi, was given to only those patients who have previously received chemotherapy. But after September 10, 2014, Xtandi was permitted to be used as treatment choice for pre–chemotherapy prostate cancer patients.

Out of 15 Prostate Drugs Market share only 4 drugs (Zytiga, Zoladex, Leuplin & Xtandi or MDV3100) have double digit market share in prostate cancer drugs market. All these four drugs together account for more than 60 percent market share. Zytiga market share is more than double from its nearest competitor Leuplin. 

Contact Us

Renub Research

USA: +1-678-302-0700

India: +91-120-421-9822

Email: info@renub.com

Website: www.renub.com 

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.